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Abstract
Background: Emmprin, a glycoprotein containing two Ig domains, is enriched on tumor cell surfaces and
stimulates matrix metalloproteinase (MMP) production by adjacent stromal cells. Its first Ig domain (ECI) contains
the biologically active site. The dependence of emmprin activity on N-glycosylation is controversial. We
investigated whether synthetic ECI with the shortest sugar is functionally active.
Methods: The whole ECI peptides carrying sugar chains, a chitobiose unit or N-linked core pentasaccharide, were
synthesized by the thioester method and added to fibroblasts to examine whether they stimulate MMP-2
production.
Results: ECI carrying a chitobiose unit, ECI-(GlcNAc) 2, but not ECI without a chitobiose unit or the chitobiose unit
alone, dose-dependently stimulated MMP-2 production by fibroblasts. ECI with longer chitobiose units, ECI-[(Man)3
(GlcNAc)2], also stimulated MMP-2 production, but the extent of its stimulation was lower than that of ECI-(GlcNAc)2.
Conclusions: Our results indicate that ECI can mimic emmprin activity when substituted with chitobiose, the
disaccharide with which N-glycosylation starts.
Background
Matrix metalloproteinases (MMPs) play an essential role
in remodeling of extracellular matrices (ECMs) involved
in various biological processes, such as inflammation, tis-
sue regeneration and tumor invasion. Among the MMPs,
gelatinase A (MMP-2) is the most abundant MMP and
frequently correlates with malignant progression and
invasive behavior of tumor cells [1]. In situ hybridization
studies of human surgical specimens have shown that
stromal fibroblasts are the predominant source of MMP-
2 in the majority of carcinomas [2-4]. Malignant cells sti-
mulate nearby fibroblasts to produce MMPs via soluble
cytokines and growth factors or through cell surface
interactions mediated by plasma membrane proteins,
such as emmprin [5]. Emmprin, also known as basigin/
CD147, is an integral plasma membrane glycoprotein of
the Ig superfamily that contains two extracellular Ig
domains [6]. Expression of emmprin is upregulated in
human malignant tumors, such as breast, lung and blad-
der carcinomas, malignant melanomas, gliomas and lym-
phomas, compared with their normal counterparts
[7-11]. In malignant tumors, emmprin acts as a modula-
tor of tumor-stroma cross-talk, since it mediates not only
MMP production but also tumor angiogenesis through
the stimulation of vascular endothelial growth factor
(VEGF) expression [12], induction of activated stromal
myofibroblasts [13], and anchorage-independent growth
and multidrug resistance in a hyaluronan-dependent
fashion [14-16]. The activity-blocking monoclonal anti-
body (mAb), E11F4, recognizes the first Ig domain (ECI)
of emmprin, implying that this region of emmprin con-
tains the structure responsible for the activity of this pro-
tein [5,6]. Moreover, it is reported that emmprin-induced
stimulation of MMP production in fibroblasts is depen-
dent on N-glycosylation of its extracellular domains
[17,18]. However, it has been reported recently that
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nonglycosylated recombinant emmprin could stimulate
fibroblasts to express the mRNAs of MMP-1, 2 and 3
[19]. The objective of the present study was to determine
whether the activity of synthetic emmprin ECI peptides,
with or without a chitobiose unit (GlcNAc-GlcNAc), the
disaccharide with which N-glycosylation starts, mimics
that of emmprin. The results showed that synthetic ECI
substituted with a chitobiose unit, but not ECI alone, sti-
mulates fibroblasts to produce MMP-2.
Methods
Peptides
ECI (34-94th a.a.) carrying a chitobiose unit or N-linked
core pentasaccharide at Asn44 was synthesized by the
thioester method as described previously (Figure 1)
[20-22]. ECI carrying one or two GlcNAc or N-linked
core pentasaccharide [(Man)3(GlcNAc)2] was dissolved
in dimethyl sulfoxide (DMSO). The final concentration
of DMSO in the culture medium was less than 0.01%.
At this concentration, the solvents alone showed no
cytotoxic effects or any detectable effects on MMP
production.
Cell culture
Human adult fibroblasts, MBT-3 and ST353, were
obtained from a metastatic tumor in the cerebellum from
a primary lung adenocarcinoma [23] and nonlesional der-
mis around nodular fasciitis [24], respectively. The tumor
cell line FU-EPS-1 was established from a patient with
epithelioid sarcoma who had not received any chemother-
apy before surgical resection [25]. These cell lines were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and anti-
biotics (100 U/ml penicillin G and 100 μg/ml streptomy-
cin) in a humidified atmosphere of 5% CO2 at 37°C.
Co-culture experiments
Co-culture experiments were performed as described
previously [24]. Briefly, cultures containing either fibro-
blasts, tumor cells or both were established in 20-mm
Figure 1 Molecular structure of the emmprin molecule and schema of synthetic ECI carrying a chitobiose unit or N-linked core
pentasaccharide. ECI, the first extracellular Ig domain; ECII, the second extracellular Ig domain.
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diameter wells containing 1.0 ml DMEM with 10% FBS.
For co-cultures, the same number (4 × 104) of fibro-
blasts and tumor cells were incubated. The cells were
allowed to attach for 24 h at 37°C, after which their cul-
ture media were replaced with fresh serum-free (SF)
DMEM containing 0.2% lactalbumin hydrolysate (LH)
(0.5 ml/well) prior to the start of the experiment.
Experiments under each condition were performed in
triplicate wells. The culture media were replaced with
fresh SF DMEM at 3 days and harvested at 6 days. The
harvested media were used for immunoblotting and
enzyme immunoassay.
Treatment of fibroblasts with ECI-(GlcNAc)1 or 2, ECI-[(Man)3
(GlcNAc)2], Asn44-(GlcNAc)2, or ECI alone
Fibroblasts were allowed to attach for 24 h in DMEM with
10% FBS, then their culture media were replaced with
fresh SF DMEM containing 0.2% LH and ECI peptides
with or without chitobiose units at various concentrations.
Experiments under each condition were performed in tri-
plicate wells. The culture media and cells were harvested
at 3 days, and used for immunoblotting, enzyme immu-
noassay, RNA extraction and Northern blot analysis. For
Northern blot analysis, cells in triplicate wells were com-
bined to isolate poly(A)+RNA enough for the assay.
Inhibition experiments using anti-emmprin blocking
antibody (UM-8D6, Ancell Corporation, Bayport, MN)
were performed as described previously [23]. Briefly, ECI
peptides with chitobiose units [ECI-(GlcNAc)2] were pre-
incubated with the blocking antibody in SF DMEM con-
taining 0.2% LH at 37°C for 45 min and then added to
fibroblasts (4 × 104). Their media were replaced once with
fresh SF DMEM containing [ECI-(GlcNAc)2] and the
blocking antibody at 3 days, and the culture media were
harvested at 6 days.
RNA isolation and Northern blot analysis
Poly(A)+RNA was isolated from cultured cells using the
Fast Track mRNA isolation kit (Invitrogen, San Diego,
CA). Northern blotting was performed as described pre-
viously [9]. Cloned cDNA (1,752 bp) encoding human
MMP-2 was used as a probe. For internal control of load-
ing, the blots were subsequently hybridized to a glyceral-
dehyde-3-phosphate dehydrogenase (G3PDH) probe
(Clontech, Mountain View, CA). The probes were radiola-
beled by random priming with 32P-CTP. For quantification
of the RNA blot analysis, the radioactivity of mRNA sig-
nals for MMP-2 was directly measured by a Bioimaging
Analyzer, FUJIX BAS2000 system (Fuji Photo Film, Tokyo,
Japan), and normalized relative to the corresponding
G3PDH mRNA signals.
Immunoblotting
SDS-PAGE and immunoblotting of conditioned media
were performed using a 5-15% gradient separating gel,
Immobilon membrane (Millipore, Bedford, MA) and a
mouse mAb to human MMP-2 (75-7F7, Fuji Chemical
Industries, Takaoka, Japan) as described previously [23].
To quantitate the relative amounts of the MMPs, the
bands on the film were subjected to image analysis
(Adobe Photoshop). Statistical analysis was performed
using Student’s t-test.
Enzyme immunoassay (EIA)
The protein concentrations of pro-MMP-2 were mea-
sured using commercially available EIA kit (Daiichi Fine
Chemical, Takaoka, Japan) using the protocols supplied
by the manufacturer. All assays were performed in tripli-
cate and statistical analyses were performed using Stu-
dent’s t-test.
Zymography
Gelatinolytic activities in conditioned media were demon-
strated using gelatin as a substrate. SDS-PAGE was per-
formed under non-reducing conditions using a 9%
separating gel containing 1 mg/ml gelatin. After electro-
phoresis, the gel was shaken gently in detergent buffer
(5 mM CaCl2, 2.5% Triton X-100, and 50 mM Tris-HCl,
pH 7.6) at room temperature for 60 min to remove the
SDS, and then incubated in reaction buffer (0.15 M NaCl,
10 mM CaCl2, 0.02% NaN3, and 50 mM Tris-HCl, pH 7.6)
at 37°C for 30 h followed by staining with 2.5% Coomassie
brilliant blue in 30% methanol and 10% acetate. Enzyme
activity was detected as a clear band on the resulting blue
background of undigested gelatin. Gel images were ana-
lyzed digitally (Adobe Photoshop) to quantitate relative
activities.
Results
Effects of ECI with or without a chitobiose unit on MMP
production by fibroblasts
Previous studies showed two important findings with
regard to emmprin activity, namely that the activity resides
in ECI [6], and that it depends on N-glycosylation of extra-
cellular domains of emmprin [17,18]. These findings
prompted us to synthesize the whole ECI with attached
sugar chains (N-glycosylation). In the first step, ECI carry-
ing one or two GlcNAc at Asn44 was synthesized. When
added to fibroblast cultures, ECI-(GlcNAc)1 or 2 stimulated
MMP-2 mRNA expression, while unsubstituted ECI had
no stimulatory effect (Figure 2). The stimulatory activity of
ECI-(GlcNAc)2 was much more than that of ECI-
(GlcNAc)1 and was dose-dependent: approximately 1.1-,
3.6- and 4.6-fold stimulation at 7, 14 and 35 μM, res-
pectively, compared to control. Stimulation was also
demonstrated at the protein level. By immunoblotting,
ECI-(GlcNAc)1 stimulated MMP-2 production by approxi-
mately 2.0-, 3.4- and 4.9-fold at 7, 14 and 35 μM, respec-
tively, compared with the control, and ECI-(GlcNAc)2
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stimulated it by approximately 6.7-, 7.2- and 8.6-fold,
respectively, at the same concentrations (Figure 3). Again,
unsubstituted ECI had no stimulatory effect. The stimu-
lated production of MMP-2 protein by ECI-(GlcNAc)2
was also confirmed by quantitative EIA (Figure 4). ECI-
(GlcNAc)2 significantly stimulated MMP-2 production
(mean ± SEM, 114 ± 9.8 and 118 ± 8.6 ng/ml) of MMP-2
at 7 and 35 μM respectively, compared to control (9.1 ±
2.4 ng/ml) and ECI alone (14.2 ± 3.3 and 15.2 ± 4.1 ng/ml
at 7 and 35 μM, respectively) (p < 0.01). The levels of
MMP-2 stimulated with ECI-(GlcNAc)2 at 7 or 35 μM
were similar to those stimulated in tumor cell-fibroblast
co-cultures (124 ± 14 ng/ml).
To rule out that (GlcNAc)2 alone stimulated MMP
synthesis in fibroblasts, Asn-(GlcNAc)2 was added to
fibroblast cultures. The results showed no stimulatory
effect for Asn-(GlcNAc)2 or unsubstituted ECI on
MMP-2 production (Figure 5), while ECI-(GlcNAc)2
stimulated MMP-2 production.
MMP-2 stimulation activity of ECI-(GlcNAc)2 vs. ECI-[(Man)3
(GlcNAc)2]
Next, we investigated whether ECI with longer chitobiose
units could induce more potent stimulation of fibroblasts
to produce larger amounts of MMP-2. Treatment with
ECI-[(Man)3(GlcNAc)2] significantly stimulated fibroblasts
to produce MMP-2 (98.7 ± 5.4 and 106 ± 11 ng/ml at 7
and 35 μM, respectively) compared to the control (24.4 ±
3.2 ng/m) (p < 0.01) (Figure 6A). However, the extents of
stimulation by ECI-[(Man)3(GlcNAc)2] were lower than
those by the same dose of ECI-(GlcNAc)2 (132 ± 7.8 and
138 ± 8.5 at 7 and 35 μM, respectively). The extents of sti-
mulation of MMP-2 production by ECI-(GlcNAc)2 were
almost similar to those by FU-EPS-1 tumor cell surface
emmprin in co-cultures of FU-EPS-1 cells and fibroblasts
(Figure 6B).
Anti-emmprin blocking antibody Inhibits the MMP-2
stimulating activity of ECI-(GlcNAc)2 peptide
To confirm that the responses in the above ECI-
(GlcNAc)2 peptide-induced stimulation of MMP-2 pro-
duction were emmprin-mediated, inhibition assay using
anti-emmprin blocking antibody was performed. EIA
showed that the anti-emmprin blocking antibody inhib-
ited (14 μM) ECI-(GlcNAc)2-induced stimulation of
MMP-2 production (inhibition by approximately 58% at
10 μg/ml and 54% at 50 μg/ml), while non-immune IgG
as control did not cause any inhibition (Figure 7).
Figure 2 Effects of ECI-(GlcNAc)1/2 on MMP-2 production by fibroblasts - Northern blotting. After culture of fibroblasts in the presence of
synthetic ECI alone or ECI-(GlcNAc)1/2 for 3 days, the extracted total RNA was subjected to Northern blotting. Top panel, representative blots.
Bottom panel, MMP-2 expression level relative to the control. Control-1, solvent control for ECI alone; control-2, solvent control for ECI-(GlcNAc)1
and 2.
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Discussion
The present study showed that the synthetic emmprin
ECI peptide can exhibit emmprin activity to stimulate
fibroblasts to produce MMP-2, when substituted with a
chitobiose unit (GlcNAc-GlcNAc). The whole ECI with-
out a chitobiose unit showed no stimulatory activity on
MMP-2 production. These findings suggest that ECI is a
key domain in determining the activity of the emmprin
molecule. Moreover, the results showed that ECI was
active, in terms of stimulating MMP-2 production, in
the presence of the shortest form of N-glycosylation.
Two groups have reported that emmprin stimulation of
MMP production in fibroblasts is dependent on N-glycosy-
lation of its extracellular domains [17,18]. The ability of the
emmprin molecule to participate in homophilic adhesion
alone is not sufficient for MMP induction because glycosy-
lation is not needed for homophilic adhesion but is essen-
tial for MMP-1 and MMP-2 induction [18]. ECI with
glycosylation, although just a short chitobiose unit, may
send a signal into the cells to upregulate MMP-2. There
are two possibilities: First, the carbohydrate side chains
may participate directly in ligand binding to a putative
fibroblast receptor. Second, they may be necessary for pre-
servation of an active molecular conformation [5]. Intrigu-
ingly, in our study, ECI substituted with only two GlcNAcs
induced MMP-2 expression at both mRNA and protein
levels. This chitobiose unit is the common structure
formed at the reducing end of N-linked carbohydrates.
Longer and more complex N-linked carbohydrates are
reported to be involved in cellular adhesion, possibly via
direct binding to lectins [26]. As for emmprin ECI, how-
ever, substitution with only two GlcNAcs was more potent
than that with the core pentasaccharide. Thus, it is more
likely that the chitobiose unit plays a role in preservation of
an active molecular conformation. The peptide structures
might be bent somehow by hydrogen bonds formed
between amino acids and carbohydrates to form an active
molecular structure. This possibility is currently under
investigation in our laboratories. Similarly, it was shown
that the adhesion domain of human CD2 bears a single N-
linked carbohydrate, and that the carbohydrate stabilizes
the protein fold by counterbalancing the unfavorable clus-
tering of five positive charges centered about lysine-61 of
CD2 [27]. Furthermore, the addition of short saccharides
(e.g., di-, tri- and tetra-saccharides) to Notch by Fringe is
postulated to increase Notch’s sensitivity to Delta-like
ligands, although they are O-linked carbohydrates [28].
This glycosylation supposedly does not affect Notch signal-
ing by directly influencing the binding between Notch and
ligands but may influence steps that occur just before the
Figure 3 Effects of ECI-(GlcNAc)1/2 on MMP-2 production by fibroblasts - western blotting. After culture of fibroblasts in the presence of
synthetic ECI alone or ECI-(GlcNAc)1/2 for 3 days, the conditioned media were subjected to western blotting. Top panel, representative blots.
Bottom panel, MMP-2 expression level relative to the control. Data are mean ± SEM (n = 3). Control-1, solvent control for ECI alone; control-2,
solvent control for ECI-(GlcNAc)1 and 2. *p < 0.01, compared with the control.
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release of the Notch intracellular domain by proteolytic
cleavages [28].
Induction of MMP-1, 2 and 3 mRNAs in uterine
fibroblasts by non-glycosylated recombinant emmprin
has been reported also [19], although a higher expres-
sion at the protein level was not confirmed. The authors
hypothesized that their recombinant emmprin main-
tained the disulfide-stabilized tertiary structures, which
let emmprin form dimers in solution and promoted
their binding to the cell surface receptors, followed by
increased MMP expression. Our study used smaller ECI
peptides so that chitobiose substitution might have been
necessary to give the peptide some tertiary structures.
Moreover, the fibroblasts used in this study were stimu-
lated to produce only MMP-2, but not MMP-1 and 3,
in response to tumor cell emmprin (data not shown).
Thus, the effect of the ECI peptide with chitobiose sub-
stitution on MMP-1 and 3 could not be examined.
Recently, the crystal structure of the extracellular por-
tion of emmprin has been determined [29]. The structure
comprises an N-terminal IgC2 domain (corresponding to
ECI in this paper) and a C-terminal IgI domain, which are
connected by a 5-residue flexible linker. This unique
domain organization leads to overall flexibility and diverse
dimerization manners of emmprin and may explain its
multifunctional character. Another possible explanation
Figure 4 Effects of ECI-(GlcNAc)1/2 on MMP-2 production by fibroblasts - enzyme immunoassay. After culture of fibroblasts in the
presence of synthetic ECI alone or ECI-(GlcNAc)1/2 for 3 days, the conditioned media were subjected to enzyme immunoassay. Data are mean ±
SEM (n = 3). Control, solvent control for ECI alone and ECI-(GlcNAc)2. *p < 0.01, compared with the control.
Figure 5 Effects of the control ECI peptide and the chitobiose unit on MMP-2 production by fibroblasts. The fibroblasts were cultured in
the presence of synthetic ECI alone, Asn-(GlcNAc)2, and ECI-(GlcNAc)2 for 3 days, and the conditioned media were subjected to western blotting
for MMP-2. Control, solvent control for Asn-(GlcNAc)2, ECI alone, and ECI-(GlcNAc)2.
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for multifunction is glycosylation, since the latter is a
highly diverse nontemplate-driven process that can gener-
ate enormous informational content [30]. The glycosylated
form of emmprin was not analyzed in the above men-
tioned crystalographic study.
In this study, ECI was shown to stimulate MMP-2
production in the presence of the shortest form of N-
glycosylation. On the contrary, we previously reported
that ECI-derived peptides inhibit emmprin-enhanced
MMP-2 production in the absence of N-glycosylation
[11,24,31]. One of the ECI-derived peptides, emp#2,
which contains a putative N-glycosylation site but shows
no glycosylation, effectively inhibited emmprin-induced
stimulation of MMP-2 production. Furthermore, emp#2
peptide effectively inhibited the enhanced invasion of
matrigel by glioblastoma cells in the co-presence of
fibroblasts [31]. These results also show biological
importance of presence of N-glycosylation in ECI.
Thus far, several lines of evidence point to the impor-
tance of emmprin in cancer biology. First, emmprin is
upregulated in a broad spectrum of malignant tumors,
including carcinomas, gliomas and lymphomas, compared
with their normal counterparts as mentioned in the Intro-
duction section. Second, emmprin promotes tumor pro-
gression as well as upregulation of MMPs in animal
models: emmprin cDNA-transfected human breast cancer
cells were considerably more tumorigenic and invasive
than plasmid-transfected cancer cells when implanted into
the nude mouse [32]. Third, as already discussed above,
emmprin may be responsible for upregulated MMPs,
Figure 6 Effects of ECI-(GlcNAc)2 or ECI-[(Man)3(GlcNAc)2] on MMP-2 production by fibroblasts. A, After culture of fibroblasts in the
presence of synthetic ECI-(GlcNAc)2 or ECI-[(Man)3(GlcNAc)2] for 3 days, the conditioned media were subjected to enzyme immunoassay. Data
are mean ± SEM (n = 3). Control, solvent control for ECI-(GlcNAc)2 and ECI-[(Man)3(GlcNAc)2]. *p < 0.01, compared with the control. B, The
conditioned media obtained as described above were subjected to gelatin zymography. At the same time, conditioned media from co-culture
experiments of FU-EPS-1 tumor cells and fibroblasts were also applied to the same gel. Fb, fibroblasts. Fb control, fibroblast cultures with solvent
control for ECI-(GlcNAc)2 and ECI-[(Man)3(GlcNAc)2].
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enhanced angiogenesis and hyaluronic acid production,
transformation of stroma fibroblasts, and drug resistance
[6,12-18,32]. In this context, it is important to elucidate
the mechanisms involved in multifunctionality of the
emmprin molecule.
Conclusions
This study indicates that ECI can mimic emmprin activ-
ity in terms of stimulating MMP-2 production by fibro-
blasts when substituted with chitobiose, the disaccharide
with which N-glycosylation starts. This synthetic glyco-
peptide may be useful for elucidating the mechanisms
involved in glycosylation-mediated emmprin activities,
which could lead to new strategies to prevent cancer
invasion and progression enhanced by emmprin.
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